Localized Prostate Cancer VL

DASL-HiCAP (ANZUP1801): The Impact of Darolutamide on Standard Therapy for Localized Very High-risk Cancer of the Prostate - Christopher Sweeney

Details
Christopher Sweeney, MD, sits down with Alicia Morgans, MD, MPH to discuss “DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Prostate Cancer,” a phase 3, 1100 patient study lead by the ANZUP group which randomizes men with high-risk prostate cancer to darolutamide or standard of care. Biographies: Christopher Sweeney, MBBS, Professor of Medicine, Harvard Medical Scho...

The Role of Neoadjuvant Therapy for Patients with Localized Prostate Cancer - Rana R. McKay

Details
Rana McKay joins Alicia Morgans to discuss the outcomes of a study investigating randomized patients with high-risk prostate cancer (Gleason ≥4+3, PSA >20, T3 disease, and lymph nodes <20 mm) to either abiraterone + prednisone + apalutamide + leuprolide (APAL) or abiraterone + prednisone + leuprolide (APL) for a total of 6 cycles (each cycle 28 days), followed by radical prostatectomy. A total of...

Active Surveillance for Low-Risk Prostate Cancer - Laurence Klotz and Peter Carroll

Details
Matt Cooperberg hosts a discussion with Peter Carroll and Laurence Klotz examining their roles in the progress of active surveillance for low-risk prostate cancer and how they incorporate this treatment into clinical practice. They discuss the change in the field from over-detection and overtreatment where radiation and surgery were the primary treatment options to the evolution of active surveill...

Study of Baseline PSA Screening of Men (45 years old) - Peter Albers

Details
Peter Albers discusses his study of baseline PSA screening of young men across the nation of Germany. The study consists of 45-year-old men who are randomized in two cohorts, one group gets a PSA immediately and the other cohort has a delay of five years. The initial PSA value determines the patient’s risk-adapted strategy and dictates the schedule of further testing. Dr. Albers states that the tr...

Radiation Therapy Advances and Technology Overview - Daniel Spratt

Details
Daniel Spratt presents on practical aspects of the technological evolution in radiation therapy during the 2019 LUGPA CME session. He focuses his presentation on technological advances in radiation therapy including a hybrid of software and hardware, which is the technology of our ability to plan radiation therapy going from a 2D to 3D to IMRT era, imaging tumors when you put a patient on a machin...

Epidemiologic Outcomes of Prostate Cancer Patients Undergoing Active Surveillance - Sigrid Carlsson

Details
Sigrid Carlsson joins Charles Ryan discussing the epidemiologic outcomes of men in the current era who are facing active surveillance. She reviews the long term data learned from the Memorial Sloan Kettering Cancer Center Experience which mirrors prior reports with low rates of metastasis or cancer-related deaths for patients on active surveillance. They also discuss the migration of pushing the e...

Exercise vs. Usual Care Among Men Opting for Active Surveillance for Prostate Cancer - June Chan

Details
At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019), Professor June Chan joins Charles Ryan to discuss her work with patients on active surveillance (AS) for prostate cancer and a current ongoing study of lifestyle modification. Early data suggest that exercise after diagnosis could help with delaying or deterring prostate cancer recurrence or progression. The AS RCT study...

Increasing Rates of Active Surveillance as the Standard of Care in Men with Low Risk Prostate Cancer- Matthew Cooperberg

Details
Matthew Cooperberg discusses active surveillance as the standard of care for men with low-risk prostate cancer as well as data from multiple registries including CaPSURE, MUSIC, AQUA, and SEER, which report increasing rates of active surveillance in men with low-risk disease. He further discusses the factors that may be driving lower uptake of active surveillance in some practices. Biographies: Ma...

ProVent Trial for Newly Diagnosed Prostate Cancer - Benjamin Lowentritt

Details
Benjamin Lowentritt and Alicia Morgans discuss the ProVent trial, the use of sipuleucel-T in newly diagnosed prostate cancer patients on active surveillance. They discuss inclusion criteria, trial design and primary outcome measures which include assessing the efficacy of sipuleucel-T in reducing reclassification to a higher Gleason grade in patients on active surveillance. Biographies: Alicia Mor...

Engagement in Long-Term Physical Activity and Lowering the Risk of Advanced Prostate Cancer - Lorelei Mucci

Details
Lorelei Mucci and Alicia Morgans discuss the findings of a large epidemiologic study examining physical activity and its influence on a wide range of biological processes including anti-inflammatory and insulin pathways, may be linked to a lower risk of prostate cancer. In addition to being one of the largest of its kind, the study stands out in that researchers were able to examine medical record...